The Future of Pharmacogenomics: Integrating Epigenetics, Nutrigenomics, and Beyond

Pharmacogenomics (PGx) has revolutionized personalized medicine by empowering the tailoring of drug treatments based on individual genetic profiles. However, the complexity of drug response mechanisms necessitates the integration of additional biological and environmental factors. This article explores integrating epigenetics, nutrigenomics, microbiomes, protein interactions, exosomes, and metabolomics with PGx to enhance personalized medicine. In addition to discussing these scientific advancements, we examine the regulatory and ethical challenges of translating multi-omics into clinical practice, including considerations of data privacy, regulatory oversight, and equitable access. By framing these factors within the context of Medication Adherence, Medication Appropriateness, and Medication Adverse Events (MA3), we aim to refine therapeutic strategies, improve drug efficacy, and minimize adverse effects, with the goal of improving personalized medicine. This approach has the potential to benefit patients, healthcare providers, payers, and the healthcare system as a whole by enabling more precise and effective treatments.

• Publication year

  2024

• Venue

  Journal of Personalized Medicine

• Publication date

  2024-11-27

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.3390/jpm14121121PMID 39728034PMCID 11677977
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Usual dietary intake and change in DNA methylation over years: EWAS in KORA FF4 and KORA fit

  2024cited by this paper
• The pharmacoepigenetic paradigm in cancer treatment

  2024cited by this paper
• Enigmatic exosomal connection in lung cancer drug resistance

  2024cited by this paper
• Systemic Metabolomic Profiles in Adult Patients with Bacterial Sepsis: Characterization of Patient Heterogeneity at the Time of Diagnosis

  2023cited by this paper
• The Implication of a Polymorphism in the Methylenetetrahydrofolate Reductase Gene in Homocysteine Metabolism and Related Civilisation Diseases

  2023cited by this paper
• Genetics of ABCB1 in Cancer

  2023cited by this paper
• Association between acetaminophen metabolites and CYP2E1 DNA methylation level in neonate cord blood in the Boston Birth Cohort

  2023cited by this paper
• Guide to Metabolomics Analysis: A Bioinformatics Workflow

  2022cited by this paper
• Maturing pharmacogenomic factors deliver improvements and cost efficiencies

  2022cited by this paper
• A brief history of epigenetics.

  2022cited by this paper
• The Challenge and Importance of Integrating Drug–Nutrient–Genome Interactions in Personalized Cardiovascular Healthcare

  2022cited by this paper
• Isolation and analysis methods of extracellular vesicles (EVs)

  2021cited by this paper
• Laboratory methods to decipher epigenetic signatures: a comparative review

  2021cited by this paper
• Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection.

  2021cited by this paper
• How Dietary Factors Affect DNA Methylation: Lesson from Epidemiological Studies

  2020cited by this paper
• Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis

  2020cited by this paper
• Tools for Analysis of the Microbiome

  2020cited by this paper
• Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients

  2020cited by this paper
• DNA methylation and histone acetylation changes to cytochrome P450 2E1 regulation in normal aging and impact on rates of drug metabolism in the liver

  2020cited by this paper
• Drug resistance in cancer: mechanisms and tackling strategies

  2020cited by this paper
• Aberrant DNA Methylation of ABC Transporters in Cancer

  2020cited by this paper
• Biomarkers of Nutrition and Health: New Tools for New Approaches

  2019cited by this paper
• RNA sequencing: the teenage years

  2019cited by this paper
• Exosomes: biogenesis, biologic function and clinical potential

  2019cited by this paper
• The Influence of Metabolism on Drug Response in Cancer

  2018cited by this paper
• Novel Applications of Metabolomics in Personalized Medicine: A Mini-Review

  2017cited by this paper
• Specific packaging and circulation of cytochromes P450, especially 2E1 isozyme, in human plasma exosomes and their implications in cellular communications.

  2017cited by this paper
• Metabolomics enables precision medicine: “A White Paper, Community Perspective”

  2016cited by this paper
• Protein-Protein Interaction Detection: Methods and Analysis

  2014cited by this paper
• Grapefruit–medication interactions: Forbidden fruit or avoidable consequences?

  2013cited by this paper
• Predicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta

  2013cited by this paper
• Food-Drug Interactions

  2012cited by this paper
• Warfarin and vitamin K intake in the era of pharmacogenetics.

  2010cited by this paper
• Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells

  2010cited by this paper
• Human CYP2E1 is regulated by miR-378.

  2010cited by this paper
• Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme

  2010cited by this paper
• Transcriptional regulation of ABC drug transporters

  2003cited by this paper
• Precipitous Release of Methyl-CpG Binding Protein 2 and Histone Deacetylase 1 from the Methylated Human Multidrug Resistance Gene (MDR1) on Activation

  2002cited by this paper
• Grapefruit juice-drug interactions.

  1998cited by this paper
• Digoxin-inactivating bacteria: identification in human gut flora.

  1983cited by this paper
• Inactivation of digoxin by the gut flora: reversal by antibiotic therapy.

  1981cited by this paper
• The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

  1972cited by this paper

• Nutritional Modulation of Biochemical Pathways in Stress Response: A Comprehensive Review

  2026cites this paper
• Therapeutic Potential of Enzymes, Neurosteroids, and Synthetic Steroids in Neurodegenerative Disorders: A Critical Review.

  2025cites this paper
• Reversing Epigenetic Dysregulation in Neurodegenerative Diseases: Mechanistic and Therapeutic Considerations

  2025cites this paper
• Artificial Intelligence and Multi-Omics in Pharmacogenomics: A New Era of Precision Medicine

  2025cites this paper
• Exosome-mediated miRNA delivery: a molecular switch for reshaping neuropathic pain therapy

  2025cites this paper
• The Potential of Nutraceutical Supplementation in Counteracting Cancer Development and Progression: A Pathophysiological Perspective

  2025cites this paper
• Pharmacogenetics of graft-versus-host disease: a path to personalized medicine.

  2025cites this paper
• A comprehensive review on diabetic cardiomyopathy (DCM): histological spectrum, diagnosis, pathogenesis, and management with conventional treatments and natural compounds

  2025cites this paper
• Exosomal biomarkers in leukemia: translational potential and regulatory challenges for precision medicine applications

  2025cites this paper
• Pharmacogenomics in Diabetes: Population-Specific Insights from Colombia

  2025cites this paper
• The Endocannabinoid System in Human Disease: Molecular Signaling, Receptor Pharmacology, and Therapeutic Innovation

  2025cites this paper
• Awareness of pharmacogenomic capabilities among physicians and pharmacists in Saudi Arabia within current clinical practice

  2025cites this paper
• Immune Checkpoint Restoration as a Therapeutic Strategy to Halt Diabetes-Driven Atherosclerosis

  2025cites this paper
• The Evolving Pharmacogenomic Toolbox in Anesthesiology.

  2025cites this paper
• Riboflavin in neurological diseases: therapeutic advances, metabolic insights, and emerging genetic strategies

  2025cites this paper